Viridian Therapeutics, Inc.\DE Quarterly Nonoperating Income (Expense) in USD from Q1 2016 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Viridian Therapeutics, Inc.\DE quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2016 to Q2 2024.
  • Viridian Therapeutics, Inc.\DE Nonoperating Income (Expense) for the quarter ending June 30, 2024 was $7.19M, a 70.8% increase year-over-year.
  • Viridian Therapeutics, Inc.\DE Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was $22.7M, a 79.1% increase year-over-year.
  • Viridian Therapeutics, Inc.\DE annual Nonoperating Income (Expense) for 2023 was $16.7M, a 277% increase from 2022.
  • Viridian Therapeutics, Inc.\DE annual Nonoperating Income (Expense) for 2022 was $4.43M, a 1306% increase from 2021.
  • Viridian Therapeutics, Inc.\DE annual Nonoperating Income (Expense) for 2021 was $315K, a 82.1% increase from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $22.7M $7.19M +$2.98M +70.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $19.7M $7.36M +$3.03M +70.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $16.7M $4.62M +$1.34M +40.8% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 $15.4M $3.56M +$2.68M +305% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 $12.7M $4.21M +$4.14M +5670% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $8.56M $4.32M +$4.13M +2105% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $4.43M $3.28M +$3.15M +2330% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 $1.28M $880K +$789K +867% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $495K $73K +$39K +115% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $456K $196K +$141K +256% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $315K $135K +$99K +275% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 $216K $91K +$82K +911% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $134K $34K +$1K +3.03% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 $133K $55K -$40K -42.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-13
Q4 2020 $173K $36K -$87K -70.7% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-11
Q3 2020 $260K $9K -$195K -95.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-05
Q2 2020 $455K $33K -$242K -88% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 $697K $95K -$244K -72% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q4 2019 $941K $123K -$241K -66.2% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-26
Q3 2019 $1.18M $204K -$158K -43.6% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 $1.34M $275K -$86K -23.8% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 $1.43M $339K +$172K +103% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q4 2018 $1.25M $364K +$206K +130% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-13
Q3 2018 $1.05M $362K +$249K +220% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 $799K $361K +$259K +254% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 $540K $167K +$137K +457% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $403K $158K +$142K +888% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-14
Q3 2017 $261K $113K +$106K +1514% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $155K $102K +$93K +1033% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-08
Q1 2017 $62K $30K +$23K +329% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 $39K $16K Oct 1, 2016 Dec 31, 2016 10-K 2018-03-15
Q3 2016 $7K Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q2 2016 $9K Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-11
Q1 2016 $7K Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.